NEW ORLEANS -- In an interview at the Society of Nuclear Medicine and Molecular Imaging annual meeting, Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, discussed new appropriate use criteria for amyloid and tau PET imaging in Alzheimer’s disease patients.
Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines
Latest in Molecular Imaging
Curium gets FDA approval for Lu-177 injection for GEP-NETs
September 15, 2026
FDA clears new PET agent for brain cancer imaging
September 14, 2026
Ratio Therapeutics, RayzeBio join forces
September 9, 2026





















